A Phase 2, Multicenter, Open-label, Single-arm Study to Evaluate the Safety and Efficacy of Niraparib in Japanese Patients With Advanced, Relapsed, High-grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received 3 or 4 Previous Chemotherapy Regimens
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 29 Jul 2019
Price : $35 *
At a glance
- Drugs Niraparib (Primary)
- Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
- Focus Therapeutic Use
- Sponsors Takeda
- 11 Apr 2019 Planned End Date changed from 30 Nov 2020 to 9 Jun 2020.
- 11 Apr 2019 Planned primary completion date changed from 31 Jul 2020 to 9 Jul 2019.
- 11 Apr 2019 Status changed from recruiting to active, no longer recruiting.